Investigation of the Cultural Adaptation, Validity, and Reliability of the Turkish Version of the CAP Questionnaire
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Questionnaire study.
- Who it may be relevant to
- Registry conditions: Osteoarthritis, Back Pain, Fibromyalgia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Investigation of the Cultural Adaptation, Validity, and Reliability of the Turkish Version of the Central Aspects of Pain (CAP) Questionnaire
Overview
The "CAP questionnaire," developed by modifying the CAP-Knee questionnaire to assess potential nociplastic pain features in painful musculoskeletal disorders, has been described. The "CAP questionnaire" is used in people with musculoskeletal pain and diagnostic subgroups of osteoarthritis, back pain, and fibromyalgia. There is no Turkish version of the CAP questionnaire. This study aims to investigate the cultural adaptation, validity, and reliability of the Turkish version of the "CAP questionnaire."
Detailed description
Chronic pain is a symptom shared by many musculoskeletal conditions, even when disease management is optimized. Musculoskeletal pathologies are reported to be an essential therapeutic target in pain management. However, these pathologies often do not adequately explain the pain or the reason for its persistence.
Central sensitization is the increased sensitivity of Central Nervous System (CNS) neurons to a standard nociceptive input. Pain that increases in intensity and distribution beyond that explained by musculoskeletal pathology has been termed "nociplastic pain." Measuring these CNS aspects of pain is a prerequisite for understanding their mechanistic basis and predicting future pain and responses to treatment. Chronic pain is associated with CNS dysfunction in several areas, including depression, anxiety, pain catastrophizing, cognitive dysfunction, sleep disturbance, and fatigue. Considering the increasing importance of assessing mood-related pain (nociplastic pain) The "CAP questionnaire," developed by modifying the CAP-Knee questionnaire to assess potential nociplastic pain features in painful musculoskeletal disorders, has been described.
Interventions
- Other Questionnaire study
Questionnaire application
Primary outcome measures
- Central Aspects of Pain Questionnaire (CAP) [Time frame: Three months]
Secondary outcome measures (6)
- BETY-Biopsychosocial Questionnaire [Time frame: Three months]
- Hospital Anxiety Depression Scale (HADS) [Time frame: Three months]
- Health Assessment Questionnaire (HAQ) [Time frame: Three months]
- Pain Catastrophizing Scale (PCS) [Time frame: Three months]
- Central Sensitisation Inventory (CSI) [Time frame: Three months]
- Short-Form of McGill's Pain Questionnaire [Time frame: Three months]
Eligibility criteria
Inclusion criteria
- People with musculoskeletal pain and in diagnoses with OA, back pain, or FM
- Above 18 years of age
- Informed consent of the participant
Exclusion criteria
- Diagnosis of uncontrolled/other clinically significant diseases (chronic obstructive pulmonary disease, congestive heart failure, endocrine system diseases, neurological, psychological diseases, etc.)
- Pregnant women
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Turkey (Türkiye) · 1 center
- Hacettepe University — Ankara
Identifiers
NCT: NCT06825650 · SBA 24/997